Synact Pharma announces outcome in the exercise of warrants, will receive approximately MSEK 32.4
On Wednesday, July 22, 2020, the exercise period for SynAct Pharma AB's (“SynAct” or “the Company”) warrants of series TO 2 (“TO 2”) ended. A total of 4,839,860 warrants of series TO 2 were exercised, corresponding to a subscription rate of approximately 98.95 percent of TO 2. SynAct is thus provided with a total of approximately MSEK 32.4 before issue costs. With the issue proceeds, the Company has secured the capital needed to finance several important milestones, such as demonstrating Proof-of-Concept for phase II studies with AP1189 within RA and NS.
CEO Jeppe Øvlesen comments:
“I would like to extend a big thank you to everyone who has shown interest and confidence in our business. We have now secured funding for phase II studies with AP1189 within RA and NS, which puts us in a good position for further development”.
Exercise of TO 2
In total, 4,839,860 TO 2 has been exercised, corresponding to a subscription rate of approximately 98.95 percent. Through TO 2, SynAct will receive approximately MSEK 32.4 before issue costs. The issue costs are estimated to amount to approximately MSEK 1.7. When the shares from TO 2 are registered with the Swedish Companies Registration Office, the total number of shares will amount to 24,406,295 and the share capital will amount to SEK 3,050,786.88.
Financial adviser, issuer and legal adviser
Sedermera Fondkommission is a financial advisor and issuer to SynAct in connection with the exercise of warrants regarding TO 2. Markets & Corporate Law Nordic AB acts as a legal advisor.
For further information on TO 2, please contact:
Sedermera Fondkommission, +46 (0) 40 615 14 10, firstname.lastname@example.org
This information is such information that SynAct Pharma AB is obliged to publish in accordance with the EU Market Abuse Regulation. The information was submitted, through the care of the above contact person, for publication on July 27, 2020.
For more information about SynAct Pharma AB, please contact:
Jeppe Øvlesen Thomas Jonassen
CEO, SynAct Pharma AB CSO, SynAct Pharma AB
About SynAct Pharma
SynAct Pharma AB conducts research and development in inflammatory diseases. The company has a platform technology based on a new class of drug candidates that targets acute exacerbations in chronic inflammatory diseases with the primary purpose of stimulating natural healing mechanisms.
Förändring i AroCells ledning
”Jag är mycket glad att Gunnar knyts närmare företaget. Hans erfarenheter och kunskaper inom onkologi och urologi är mycket värdefulla för AroCell och Gunnar har tidigare haft ett betydande bidrag i sin roll som styrelsemedlem och inom specifika konsultuppdrag”, säger Michael Brobjer, VD på AroCell....
Changes in AroCell's management
“I am very pleased that Gunnar is taking on this position. His experience and knowledge in oncology and urology are very valuable for AroCell and Gunnar has previously made significant contributions in his role as a board member and in specific consulting assignments ", says Michael Brobjer, CEO...
Tiziana Life Sciences plc Announces Closing of $57.25 Million Offering
LONDON, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (the "Company" or "Tiziana"), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announces the closing of its registered direct offering...
QuiaPEG avser att listas på Nasdaq First North Growth Market
QuiaPEG Pharmaceuticals Holding AB (”QuiaPEG” eller ”Bolaget”) har påbörjat processen mot ett listbyte till Nasdaq First North Growth Market och har fått ett preliminärt och villkorat besked om att bolaget uppfyller noteringskraven. Första dag för handel på Nasdaq First North Growth Market planeras...